|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Psychemedics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Psychemedics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
12-16-2022 Insider Buy |
Michael I. Schaffer VP of Laboratory Operations |
$4.95
CAGR »
|
$495.00 100 shares |
4-20-2022 Insider Buy |
Peter Kamin >10% Owner |
$6.59
CAGR »
|
$284,423.96 43,143 shares |
4-8-2022 Insider Buy |
Peter Kamin >10% Owner |
$6.74
CAGR »
|
$47,200.00 7,000 shares |
3-31-2022 Insider Buy |
Peter Kamin >10% Owner |
$6.89
CAGR »
|
$85,516.20 12,403 shares |
12-11-2020 Insider Buy |
Fred J. Weinert Director |
$4.95
CAGR »
|
$4,950.00 1,000 shares |
12-8-2020 Insider Buy |
Raymond C. Kubacki Jr. Chairman, CEO & President |
$5.00
CAGR »
|
$5,000.00 1,000 shares |
11-18-2020 Insider Buy |
Michael I. Schaffer VP of Laboratory Operations |
$4.20
CAGR »
|
$2,100.00 500 shares |
11-13-2020 Insider Buy |
Fred J. Weinert Director |
$3.92
CAGR »
|
$7,840.00 2,000 shares |
11-12-2020 Insider Buy |
Raymond C. Kubacki Jr. Chairman, CEO & President |
$3.86
CAGR »
|
$7,720.00 2,000 shares |
11-13-2020 Insider Buy |
A. Clinton Allen Director |
$3.99
CAGR »
|
$7,980.00 2,000 shares |
6-14-2019 Insider Buy |
Raymond C. Kubacki Jr. Chairman, CEO & President |
$9.99
CAGR »
|
$9,990.00 1,000 shares |
6-5-2019 Insider Buy |
Charles M. Doucot Vice President Sales & Mktg |
$9.90
CAGR »
|
$4,950.50 500 shares |
11-14-2017 Insider Buy |
Raymond C. Kubacki Jr. Chairman, CEO & President |
$16.88
CAGR »
|
$16,880.00 1,000 shares |
3-2-2016 Insider Buy |
Harry F. Connick Sr. Director |
$12.83
CAGR »
|
$8,981.00 700 shares |
2-26-2016 Insider Buy |
Harry F. Connick Sr. Director |
$12.63
CAGR »
|
$12,634.00 1,000 shares |
2-24-2016 Insider Buy |
Harry F. Connick Sr. Director |
$12.36
CAGR »
|
$24,726.00 2,000 shares |
2-19-2016 Insider Buy |
Harry F. Connick Sr. Director |
$11.95
CAGR »
|
$11,950.00 1,000 shares |
2-16-2016 Insider Buy |
Michael I. Schaffer VP of Laboratory Operations |
$11.09
CAGR »
|
$49,982.63 4,507 shares |
6-15-2012 Insider Buy |
Neil Lerner VP - Finance |
$9.80
CAGR »
|
$24,500.00 2,500 shares |
5-25-2011 Insider Buy |
Neil Lerner VP - Finance |
$10.01
CAGR »
|
$59,008.95 5,895 shares |
3-17-2011 Insider Buy |
Neil Lerner Vice President and Controller |
$9.09
CAGR »
|
$18,182.00 2,000 shares |
3-6-2009 Insider Buy |
Raymond C. Kubacki Jr. Chairman, CEO & President |
$4.27
CAGR »
|
$4,269.00 1,000 shares |
Also See: Institutional Holders of PMD
Also See: SEC filings
Below we present the annualized performance delivered by Psychemedics stock since 12-16-2022 (the date of the most recent
insider purchase). The performance of the investment from the time Psychemedics insider buying occurred is the ultimate
test of whether insiders were right about PMD being a good buy.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
12/19/2022 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$5.00 |
|
End price/share: |
$2.62 |
|
Starting shares: |
2,000.00 |
|
Ending shares: |
2,054.64 |
|
Dividends reinvested/share: |
$0.14 |
|
Total return: |
-46.17% |
|
Average Annual Total Return: |
-36.49% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,382.71 |
|
Years: |
1.36 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/19/2022 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$5.00 |
|
End price/share: |
$2.62 |
|
Dividends collected/share: |
$0.14 |
|
Total return: |
-44.80% |
|
Average Annual Total Return: |
-35.31% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,519.62 |
|
Years: |
1.36 |
|
Psychemedics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Psychemedics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding PMD
|
|